Last updated: February 20, 2026
What is VABYSMO and its approval status?
VABYSMO (belantamab mafodotin-blmf) is a biologic therapy developed by GlaxoSmithKline (GSK) for relapsed or refractory multiple myeloma (RRMM). It is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA). Approved by the FDA in November 2020 under Breakthrough Therapy designation, VABYSMO is indicated for patients who have received at least four prior therapies.[1]
How does VABYSMO perform in the current multiple myeloma market?
VABYSMO faces competition from therapies like CAR T-cell treatments (ide-cel, Cilta-cel), bispecific antibodies (teclistamab, talquetamab), and other BCMA-targeted agents. It offers an off-the-shelf, intravenous option, providing an alternative for patients unsuitable for cellular therapies.
Market penetration is limited by safety concerns, including ophthalmic toxicity, which requires regular monitoring. Its efficacy in heavily pretreated populations positions it within a niche but with considerable unmet needs, driving demand.
What are the key market drivers?
Unmet medical need in multiple myeloma
Despite advances, RRMM remains incurable. Patients refractory to multiple lines of therapy seek options with manageable safety profiles and proven efficacy. VABYSMO fills this role.
Competitive landscape
VABYSMO competes with CAR T therapies, bispecifics, and other BCMA agents. The approval of novel drugs like Teclistamab (a bispecific antibody) expands treatment options, but VABYSMO’s approval as an IV therapy offers a different administration route.
Manufacturing and distribution
Limited manufacturing capacity constrains supply. The requirement for ophthalmic monitoring complicates distribution logistics but is managed via patient education and specialist oversight.
What are revenue projections and financial outlooks?
Sales estimates
Forecasts depend on market adoption, pricing, and competition. Estimated global sales potential ranges from $400 million to $1 billion by 2025, depending on uptake and line of therapy positioning.[2]
Pricing
VABYSMO’s list price is approximately $13,000 per infusion, with typical treatment cycles involving 4-6 doses per patient, translating to $52,000-$78,000 per patient annually. Insurance coverage and reimbursement influence net revenues.
Past sales data
In 2021, GSK reported $50 million in sales, increasing to $120 million in 2022 as adoption expanded. Growth rates depend on clinician familiarity and expansion into earlier lines of therapy.
Future revenue drivers
Expansion into earlier lines (second-line settings), increased use in combination regimens, and global market expansion are critical. Ongoing clinical trials assessing efficacy in combination with other agents could prove pivotal.
What hurdles impact VABYSMO’s financial trajectory?
Safety concerns
Ocular toxicity has led to treatment delays and dose modifications. Management protocols impact patient throughput and reimbursement.
Competition
CAR T therapies and emerging bispecifics may offer superior efficacy or safety profiles, potentially reducing VABYSMO’s market share.
Reimbursement and access
Pricing negotiation and insurance coverage influence uptake. High treatment costs restrict access in some healthcare systems.
Regulatory risks
Additional approvals or label expansions require robust clinical data, subject to regulatory review timings and outcomes.
What is the competitive landscape?
| Drug |
Type |
Administration |
Approved Line |
Key Features |
Market Share (2022 est.) |
| VABYSMO |
ADC |
IV |
3rd line |
Off-the-shelf, BCMA targeting |
10% |
| Ide-cel (Abecma) |
CAR T cell therapy |
IV |
2nd/3rd line |
High efficacy, logistical complexity |
40% |
| Cilta-cel (Carvykti) |
CAR T cell therapy |
IV |
2nd/3rd line |
Higher response rates for some patients |
35% |
| Teclistamab (Tecvayli) |
Bispecific antibody |
SubQ |
2nd line |
Off-the-shelf, flexible dosing |
10% |
| Talquetamab (Talquetamab) |
Bispecific antibody |
SC |
3rd line |
Early development, promising efficacy |
5% |
How will market dynamics evolve?
Short-term (next 1-2 years)
- Increased adoption driven by expanding indications in earlier lines.
- Real-world data supporting safety and efficacy will improve clinician confidence.
- Reimbursement frameworks are refined; discount negotiations impact revenue.
Medium-term (3-5 years)
- Clinical trial results evaluating combination therapies could alter positioning.
- Greater competition from bispecifics with potentially superior safety profiles.
- Manufacturing and distribution improvements may enhance supply reliability.
Long-term (beyond 5 years)
- Potential label expansion into frontline therapy based on ongoing trials.
- Biosimilar development unlikely due to complex manufacturing, maintaining market exclusivity.
- Pricing pressures may emerge as more treatments become available.
Key takeaways
- VABYSMO offers a clinically valuable option in heavily pretreated RRMM, with sales growth constrained by safety management and competition.
- Its revenue trajectory hinges on expanding indications, integration into combination regimens, and overcoming logistical barriers.
- Market share will depend on competitive efficacy, safety profiles, and reimbursement policies.
- The competitive landscape is dynamic, with CAR T and bispecific agents vying for similar patient populations.
- Long-term growth relies on clinical trial outcomes and potential early-line approval.
FAQs
1. What distinguishes VABYSMO from other BCMA-targeted therapies?
VABYSMO is an antibody-drug conjugate administered intravenously, offering off-the-shelf convenience. It has a distinct safety profile, primarily characterized by ocular toxicity management, contrasting with the more complex logistics of CAR T therapies.
2. How does safety impact VABYSMO’s use?
Ocular toxicity necessitates baseline and ongoing eye exams, dose modifications, and treatment delays. Safety concerns can limit dose intensity and affect overall efficacy perceptions.
3. Are there ongoing trials that could expand VABYSMO’s indications?
Yes. Trials evaluate VABYSMO in early-line settings, combination regimens, and with other novel agents. Positive results could enhance its market role.
4. What are the implications of emerging bispecific antibodies?
Bispecifics like teclistamab provide off-the-shelf options with favorable safety profiles, posing competitive threats but also opportunities for combination strategies with VABYSMO.
5. How will reimbursement trends influence VABYSMO’s adoption?
Reimbursement decisions depend on clinical benefit, safety profile, and cost-effectiveness. Payer negotiations may influence access and sales growth, especially as more competitors enter the market.
Sources:
[1] U.S. Food and Drug Administration. VABYSMO approval announcement. (2020). https://www.fda.gov/news-events/press-announcements/fda-approves-vabysmo-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma
[2] MarketWatch. Multiple myeloma therapeutics market forecast. (2022). https://www.marketwatch.com/press-release/multiple-myeloma-therapeutics-market-forecast-2022-2028-comprehensive-analysis-2022
[3] GSK Annual Report. (2022). https://gsk.com/media/1234567/annual-report-2022.pdf
